Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 18;40(4):1001-1004.
doi: 10.1002/joa3.13100. eCollection 2024 Aug.

In-hospital outcomes among amyloidosis patients with atrial fibrillation: A propensity score-matched analysis

Yong-Hao Yeo  1 , Boon-Jian San  2 , Qi-Xuan Ang  3 , Min-Choon Tan  4   5 , Jian Liang Tan  6
Affiliations

In-hospital outcomes among amyloidosis patients with atrial fibrillation: A propensity score-matched analysis

Yong-Hao Yeo et al. J Arrhythm. .

Abstract

Background: The impact of atrial fibrillation (AF) among patients with amyloidosis on in-hospital outcomes is not well-established. We aimed to examine in-hospital outcomes among patients admitted with a primary diagnosis of AF with and without amyloidosis.

Methods and results: We queried the Nationwide Readmissions Database to compare the in-hospital outcomes among AF patients with and without amyloidosis. Our study demonstrated that in-hospital all-cause mortality, adverse events, and 30-day readmission were comparable between the two groups.

Conclusions: Patients with AF and concurrent amyloidosis did not have worse in-hospital outcomes than those with AF alone.

Keywords: amyloidosis; atrial fibrillation; in‐hospital outcomes; propensity score matching.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interests for this article.

Figures

FIGURE 1
FIGURE 1
Percentage of atrial fibrillation admissions with amyloidosis from 2017 to 2020.
FIGURE 2
FIGURE 2
Comparison of in‐hospital outcomes between atrial fibrillation admissions with and without amyloidosis. (A) Before propensity score matching. (B) After propensity score matching.
See this image and copyright information in PMC

References

    1. Zhang C, Huang X, Li J. Light chain amyloidosis: where are the light chains from and how they play their pathogenic role? Blood Rev. 2017;31(4):261–270. - PubMed
    1. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(4):351–361. - PubMed
    1. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2015;13(11):1195–1211. - PubMed
    1. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300. - PMC - PubMed
    1. Papathanasiou M, Jakstaite AM, Oubari S, Siebermair J, Wakili R, Hoffmann J, et al. Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis. ESC Heart Fail. 2022;9(3):1740–1748. - PMC - PubMed

LinkOut - more resources